This website is intended for healthcare professionals only

touchONCOLOGY

Search

Respiratory System, 3D illustration of human anatomy highlighting the esophagus.

Trending Topic

Developed by Touch

The microbiome and mycobiome in esophageal cancer: Implications for pathogenesis, detection and treatment

Margaret Comer, Hubert Chen, Michael K Gibson

Esophageal cancer (EC) is a major global health concern, ranking as the 11th most commonly diagnosed cancer and the seventh leading cause of cancer-related deaths worldwide, with an estimated 494,320 new cases and 441,994 deaths in 2024.1 Esophageal squamous cell carcinoma (ESCC) remains the predominant subtype globally (84% of new cases), while esophageal adenocarcinoma (EAC) […]

touchREVIEWS in Oncology & Haematology. 2026;22(2):Online ahead of journal publication

Gastrointestinal Cancers

Ken Kato, ASCO 2023: Highlights in upper gastrointestinal cancers

7 mins

Published Online: Jun 16th 2023

touchONCOLOGY are joined by editorial board member Dr Ken Kato (National Cancer Centre Hospital, Tokyo, Japan) to discuss a few of his highlights from the 2023 American Society of Clinical Oncology (ASCO) annual meeting.

ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer (00:20)

KEYNOTE-859 Interim Analysis: Overall Survival Benefit for First-Line Pembrolizumab in Advanced Gastric Cancer (04:00)

Disclosures: Ken Kato has received grant/research support from: ONO and BMS; he is a member of the advisory Board for ONO, BMS, Chugai, Daiichi Sankyo and AstraZeneca and a speaker’s bureau participant with ONO, BMS and MSD.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.

Filmed as a highlight of ASCO 2023

Access more content on Gastrointestinal Cancers here

3D medical animation of melanoma cancer cells

Trending Topic

Developed by Touch

#ASCO25: ATOMIC trial shows atezolizumab halves recurrence in stage III dMMR colon cancer

Frank Sinicrope

Dr Frank Sinicrope presented results from the ATOMIC trial at #ASCO25, showing that adding atezolizumab to adjuvant FOLFOX halved the risk of recurrence or death in stage III dMMR colon cancer. With no major safety concerns, the findings support chemo-immunotherapy as a new standard of care for this patient group.

Related Videos in Gastrointestinal Cancers

Developed by Touch

Transarterial chemoembolization with lenvatinib and pembrolizumab showed improvement in progression-free survival for hepatocellular carcinoma

Joseph Llovet

touchONCOLOGY coverage of data presented at European Society of Medical Oncology (ESMO) 2024 Annual Congress The LEAP-012 trial is a phase III, randomized, double-blind study that evaluated the efficacy and safety of combining lenvatinib and pembrolizumab with transarterial chemoembolization (TACE) compared ...

Key data in gastrointestinal cancer: ESOPEC, TRANSMET, COLLISION, ARC-9

Michael Cecchini

Practice-changing data in the field of gastrointestinal cancer was presented at ASCO 2024. To understand these, as well as the other highlights from the meeting, we spoke with Assistant Professor of Medicine (Medical Oncology), Yale School of Medicine, Dr Michael Cecchini. In this interview, Dr Cecchini discusses the findings from the ESOPEC (NCT02509286), TRANSMET (NCT02597348), COLLISION (NCT03088150), ARC-9 (NCT04660812), ABBV-400 (NCT05029882) and other presentations, offering his valuable insights into the impact the results could have on clinical practice.

Developed by Touch

Upper gastrointestinal cancer highlights - KEYNOTE-585, KEYNOTE-811, MATTERHORN and SANO: Ken Kato, ASCO 2023

Data released from the KEYNOTE-585 (NCT03221426), KEYNOTE-811 (NCT03615326), MATTERHORN (NCT04592913) and SANO (NCT05491616) trials, were some of the most anticipated results and highlights in upper gastrointestinal cancer presented at EMSO 2023. To summarise the findings from these key studies and their ...

Developed by Touch

Thierry André, ASCO 2023: The SOLISTICE phase III study, trifluridine/tipiracil+bevacizumab in patients with unresectable metastatic colorectal cancer

The SOLISTICE phase III study aimed to assess trifluridine/tipiracil+bevacizumab in patients with unresectable metastatic colorectal cancer. In this touchONCOLOGY interview, we speak with Dr Thierry André (Hôpital Saint-Antoine, Paris, France) to discuss the rationale for the use ...

Developed by Touch

Michael K Gibson, ASCO 2023: Highlights in upper GI oncology

touchONCOLOGY spoke with editorial board member Michael K Gibson (Vanderbilt University, Nashville, TN, USA) to discuss his highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting, 2–6, June 2023 in the field of upper GI oncology, including the phase 3 ATTRACTION-5 ...

Developed by Touch

Ben Weinberg, ASCO 2023: Highlights from the PROSPECT, AtezoTRIBE, D-ToRCH and DESTINY-CRC02 trials

touchONCOLOGY spoke with editorial board member Ben Weinberg (Georgetown University, Washington, DC, USA) to discuss his highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting, 2–6, June 2023. This includes data from the Plenary Session randomized phase 3 noninferiority PROSPECT trial, ...

Developed by Touch

Michael Pishvaian, AACR 2023: TIGeR-PaC phase III trial, intra-arterial gemcitabine for patients with locally advanced pancreatic cancer

Treatment of locally advanced pancreatic cancer has really primarily consisted of systemic intravenous chemotherapy. The TIGeR-PaC trial is aiming to assess if an alternative treatment mode, intra-arterial delivery of gemcitabine, improves overall survival. In this touchONCOLOGY interview, we speak with ...

Developed by Touch

Michael Pishvaian, AACR 2023: Challenges in the treatment of locally advanced pancreatic cancer

Locally advanced pancreatic cancer represents around 30% of all newly diagnosed pancreatic cancers and can be challenging to treat. In this touchONCOLOGY interview, we speak with Dr Michael Pishvaian (Johns Hopkins University School of Medicine, Baltimore, MD, USA) to discuss the ...

Developed by Touch

Angela Lamarca, ESMO 2022: ABC-06 trial, quality of life results - Symptom-control with FOLFOX in the treatment of advanced biliary cancers

The ABC-06 clinical trial established active-symptom control + oxaliplatin/5-FU chemotherapy (FOLFOX) as the standard of care treatment after Cisplatin and Gemcitabine for advanced biliary cancers. Dr Angela Lamarca (Fundación Jiménez Diaz University Hospital, Madrid, Spain) joins touchONCOLOGY to ...

Developed by Touch

Alvaro Arjona-Sanchez, ESMO 2022: HIPECT4 phase 3 trial investigating the efficacy and safety of adjuvant HIPEC in patients with locally advanced colon cancer

Peritoneal metastasis in locally advanced colon cancer has a poor prognosis from 3 years post surgical resection. Dr Alvaro Arjona-Sanchez (Institute of Biomedical Research IMIBIC, University Hospital Reina Sofia, Cordoba, Spain) joins touchONCOLOGY to discuss the HIPECT4 phase 3 trial investigating the ...

Developed by Touch

Myriam Chalabi, ESMO 2022: Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: the NICHE-2 study

Neoadjuvant immunotherapy has shown promising responses in several cancer types. In this touchONCOLOGY interview Dr Myriam Chalabi (Netherlands Cancer Institute, Amsterdam, Netherlands) discusses the NICHE-2 study results, investigating patients with non-metastatic deficient DNA mismatch repair (dMMR) colon cancer, treated with ...

Developed by Touch

John Marshall, ASCO 2022: Highlights in upper gastrointestinal cancers - K-Umbrella study, phase 2 trial of the AIO, phase Ib/II study of CLDN18.2 CAR T-cell therapy

Prof. John Marshall (Ruesch Center for the Cure of Gastrointestinal Cancer, and, Georgetown University Hospital, Washington, DC, USA) joins us to discuss the major highlights in upper gastrointestinal cancers. Prof. Marshall highlights the K-UMBRELLA study, a biomarker-integrated trial for second-line ...

Latest articles videos and clinical updates - straight to your inbox

Sign Up

Login

Sign Up FREE

Log into your Touch Account

Keep track of your clinical interests and newsletter subscriptions.

Error:

Forgot Password?

Or log in with

By proceeding, you agree to our terms & conditions.

For information about how we
use your data, see our privacy policy.

Register now for FREE Access

Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.

Sign up with an Email

Sign up with Google

Sign up with Facebook

Sign up with LinkedIn

Sign up with Microsoft

Already have an Account?

Login

Sign up with an Email

Or use a Social Account.

Error:

By clicking sign up you agree to the website
terms & conditions and privacy policy.

Register now for FREE access

Already registered? Login below.

Register

Login